Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector
- PMID: 22174877
- PMCID: PMC3235158
- DOI: 10.1371/journal.pone.0028719
Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector
Abstract
Direct cellular reprogramming is a powerful new tool for regenerative medicine. In efforts to understand and treat Parkinson's Disease (PD), which is marked by the degeneration of dopaminergic neurons in the midbrain, direct reprogramming provides a valuable new source of these cells. Astrocytes, the most plentiful cells in the central nervous system, are an ideal starting population for the direct generation of dopaminergic neurons. In addition to their potential utility in cell replacement therapies for PD or in modeling the disease in vitro, astrocyte-derived dopaminergic neurons offer the prospect of direct in vivo reprogramming within the brain. As a first step toward this goal, we report the reprogramming of astrocytes to dopaminergic neurons using three transcription factors - ASCL1, LMX1B, and NURR1 - delivered in a single polycistronic lentiviral vector. The process is efficient, with 18.2±1.5% of cells expressing markers of dopaminergic neurons after two weeks. The neurons exhibit expression profiles and electrophysiological characteristics consistent with midbrain dopaminergic neurons, notably including spontaneous pacemaking activity, stimulated release of dopamine, and calcium oscillations. The present study is the first demonstration that a single vector can mediate reprogramming to dopaminergic neurons, and indicates that astrocytes are an ideal starting population for the direct generation of dopaminergic neurons.
Conflict of interest statement
Figures




Similar articles
-
ASCL1-mediated direct reprogramming: converting ventral midbrain astrocytes into dopaminergic neurons for Parkinson's disease therapy.BMB Rep. 2024 Aug;57(8):363-368. doi: 10.5483/BMBRep.2023-0222. BMB Rep. 2024. PMID: 38649147 Free PMC article.
-
Reprogramming astrocytes into dopaminergic neurons to restore motor dysfunction in Parkinson's disease model rats.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Sept 28;49(9):1377-1389. doi: 10.11817/j.issn.1672-7347.2024.240078. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 39931768 Free PMC article. Chinese, English.
-
Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells.Hum Gene Ther. 2012 Jan;23(1):56-69. doi: 10.1089/hum.2011.054. Epub 2011 Nov 17. Hum Gene Ther. 2012. PMID: 21877920 Free PMC article.
-
How to make a midbrain dopaminergic neuron.Development. 2015 Jun 1;142(11):1918-36. doi: 10.1242/dev.097394. Development. 2015. PMID: 26015536 Review.
-
Cell reprogramming approaches in gene- and cell-based therapies for Parkinson's disease.J Control Release. 2018 Sep 28;286:114-124. doi: 10.1016/j.jconrel.2018.07.017. Epub 2018 Jul 17. J Control Release. 2018. PMID: 30026082 Review.
Cited by
-
From "directed differentiation" to "neuronal induction": modeling neuropsychiatric disease.Biomark Insights. 2015 Apr 27;10(Suppl 1):31-41. doi: 10.4137/BMI.S20066. eCollection 2015. Biomark Insights. 2015. PMID: 26045654 Free PMC article. Review.
-
Nrf2/Wnt resilience orchestrates rejuvenation of glia-neuron dialogue in Parkinson's disease.Redox Biol. 2020 Sep;36:101664. doi: 10.1016/j.redox.2020.101664. Epub 2020 Aug 1. Redox Biol. 2020. PMID: 32863224 Free PMC article. Review.
-
Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease.Front Cell Neurosci. 2018 Nov 9;12:413. doi: 10.3389/fncel.2018.00413. eCollection 2018. Front Cell Neurosci. 2018. PMID: 30483063 Free PMC article. Review.
-
Crosstalk of Astrocytes and Other Cells during Ischemic Stroke.Life (Basel). 2022 Jun 17;12(6):910. doi: 10.3390/life12060910. Life (Basel). 2022. PMID: 35743941 Free PMC article. Review.
-
Prospects for engineering neurons from local neocortical cell populations as cell-mediated therapy for neurological disorders.J Comp Neurol. 2014 Aug 15;522(12):2857-76. doi: 10.1002/cne.23618. Epub 2014 May 13. J Comp Neurol. 2014. PMID: 24756774 Free PMC article. Review.
References
-
- Wakeman DR, Dodiya HB, Kordower JH. Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011;78:126–158. - PubMed
-
- Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710–719. - PubMed
-
- Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 2001;60:741–752. - PubMed
-
- Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247:574–577. - PubMed
-
- Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54:403–414. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials